Corcept Completes Enrollment In Pivotal Phase 3 Rosella Trial Of Relacorilant In Patients With Platinum-Resistant Ovarian Cancer
Corcept完成了针对铂耐药卵巢癌患者的Relacorilant的关键性3期Rosela试验的入组
Corcept Completes Enrollment In Pivotal Phase 3 Rosella Trial Of Relacorilant In Patients With Platinum-Resistant Ovarian Cancer
Corcept完成了针对铂耐药卵巢癌患者的Relacorilant的关键性3期Rosela试验的入组
使用浏览器的分享功能,分享给你的好友吧